A pilot investigation of high-frequency audiometry in obscure auditory dysfunction (OAD) patients.

Br J Audiol

Department of Speech Pathology and Audiology, University of the Witwatersrand, Johannesburg, South Africa.

Published: August 1996

The diagnosis of obscure auditory dysfunction (OAD) has been an elusive one, based primarily upon reports of poor speech perception in noise by the patient. Basic audiometric testing reveals hearing within normal threshold limits and it is thought that there may, in part be some subtle psychoacoustic and/or central auditory deficits causing this phenomenon. The use of high-frequency audiometry (HFA) as a test of subclinical cochlear damage has been well documented, especially to monitor the early effects of noise exposure and ototoxic drugs. However, it has not been used in the diagnosis of OAD patients. This study examines the use of HFA as an aid to the understanding of OAD pathophysiology. HFA was conducted on nine OAD subjects, each matched to two controls. Results indicate an elevated threshold amongst all frequencies (10-20 kHz) in OAD patients with significant differences occurring at 10, 14, 16 and 20 kHz. It could be postulated that OAD in fact, is the product of an ultra-high-frequency hearing impairment and its psychoacoustic sequelae. Furthermore, HFA may be a useful inclusion in a diagnostic test battery for OAD status. However, the degree to which it can be used may be limited due to the large intersubject variability in HFA thresholds in the normal population. It is suggested that further investigations into the ultra-high-frequency hearing abilities of OAD patients should be completed in the future.

Download full-text PDF

Source
http://dx.doi.org/10.3109/03005369609076770DOI Listing

Publication Analysis

Top Keywords

oad patients
16
oad
9
high-frequency audiometry
8
obscure auditory
8
auditory dysfunction
8
dysfunction oad
8
ultra-high-frequency hearing
8
hfa
5
pilot investigation
4
investigation high-frequency
4

Similar Publications

The precise mechanisms behind early embryonic arrest due to sperm-related factors and the most effective strategies are not yet fully understood. Here, we present two cases of male infertility linked to novel variants, associated with oligoasthenoteratozoospermia (OAT) and early embryonic arrest. To investigate the underlying mechanisms and promising therapeutic approaches, knock-in and knock-out mice were generated.

View Article and Find Full Text PDF

Assessing the Risk of Kidney Stone Development in Patients With Idiopathic Intracranial Hypertension Treated With Carbonic Anhydrase Inhibitors.

J Neuroophthalmol

December 2024

College of Medicine (JM, AGL), Texas A&M University, Houston, Texas; Department of Ophthalmology (SAA, OAD, AGL), Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas; Department of Ophthalmology (SAA), The University of Jordan, Amman, Jordan; Department of Ophthalmology (OAD), Hashemite University, Amman, Jordan; Department of Ophthalmology (AL, AGL), Cullen Eye Institute, Baylor College of Medicine, Houston, Texas; Departments of Ophthalmology, Neurology, and Neurosurgery (AGL), Weill Cornell Medicine, New York, New York; Department of Ophthalmology (AGL), University of Texas MD Anderson Cancer Center, Houston, Texas; and Department of Ophthalmology (AGL), The University of Iowa Hospitals and Clinics, Iowa City, Iowa.

Background: The prevalence of idiopathic intracranial hypertension (IIH) is rising with the global obesity epidemic. Carbonic anhydrase inhibitors (CAIs), such as acetazolamide, have been shown to be effective in IIH but can also lead to kidney stone formation. This study evaluates the risk of kidney stone development in patients with IIH treated with CAIs.

View Article and Find Full Text PDF

Background: Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested "Armed" OAds show limited antitumor effects in patients with various solid tumors even with increased dosages and multiple injections. We developed a binary oncolytic/helper-dependent adenovirus system (CAdVEC), in which tumors are coinfected with an OAd and a non-replicating helper-dependent Ad (HDAd).

View Article and Find Full Text PDF

Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity.

J Immunother Cancer

December 2024

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

Article Synopsis
  • CD47 antibody-engineered oncolytic viruses (oAd-αCD47) were used to improve immune responses against tumors, but the effect of an acidic tumor microenvironment (TME) on this treatment was unexplored.
  • Researchers employed various techniques to assess how oAd-αCD47 interacts with the TME, identifying sodium bicarbonate (NaBi) as a key agent that enhances antitumor effects in that challenging environment.
  • The combination of NaBi and oAd-αCD47 significantly inhibited tumor growth in mouse models by altering immune cell ratios and improving metabolic functions, leading to a more robust immune response against tumors.
View Article and Find Full Text PDF
Article Synopsis
  • - Cell-cell communication (CCC) involves interactions across different scales, from large clusters of cells to individual cell pairs, making it a complex hierarchical structure influenced by signaling molecules like ligands and receptors.
  • - Current methods for studying CCC mainly focus on pre-defined groups and overlook the inherent hierarchical organization that affects how cells communicate.
  • - The newly developed computational framework, CrossChat, utilizes a multi-resolution clustering method and tree detection approach to analyze and understand these hierarchical structures in CCC, as demonstrated through various datasets related to COVID-19 and embryonic development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!